Alto Neuroscience Balance Sheet
NYSE: ANROHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Alto Neuroscience financial position
At the end of fiscal 2025, Alto Neuroscience reported total assets of $184.7 million, up 4.0% from a year earlier against total liabilities of $33.5 million. Shareholders' equity stood at $151.1 million, or 81.8% of assets. The company held $176.5 million in cash and equivalents against $16.8 million of debt, a net cash position of $159.7 million.
The current ratio (current assets divided by current liabilities) was 15.69, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.11.
Summary generated from market data by MetaCap's automated system. Methodology
Alto Neuroscience balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 |
|---|---|---|---|
| Cash & Equivalents | 176.48M | 168.23M | 82.55M |
| Total Current Assets | 177.72M | 169.34M | 85.39M |
| Property, Plant & Equipment | 1.87M | 2.67M | 1.11M |
| Total Assets | 184.69M | 177.54M | 86.63M |
| Accounts Payable | 1.88M | 1.58M | 1.07M |
| Short-Term Debt | 585.00K | 0 | 0 |
| Total Current Liabilities | 11.32M | 10.01M | 5.61M |
| Long-Term Debt | 16.17M | 10.25M | 9.86M |
| Total Liabilities | 33.55M | 26.08M | 16.82M |
| Shareholders' Equity | 151.14M | 151.46M | -71.67M |
| Retained Earnings | -201.63M | -138.40M | -76.97M |
| Total Debt | 16.76M | 10.25M | 9.86M |
| Net Cash (Debt) | 159.73M | 157.97M | 72.69M |
| Shares Outstanding | 31.92M | 26.99M | 3.83M |
This table shows 3 annual periods of Alto Neuroscience's balance sheet, from FY 2025 back to FY 2023, across 14 line items including cash & equivalents, total current assets, property, plant & equipment. Values in USD; B = billions, M = millions. Fiscal periods follow ANRO's reporting calendar. What is a balance sheet?